Biotech


  • Neuron ALS
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip
    Q&A

    Biogen partner NeuroSense seeks a role in the ALS revolution

    Results from a mid-stage study for a new ALS drug have been strong, and NeuroSense is looking to join a small but sturdy wave of companies bringing new treatments to market.

    By Feb. 29, 2024
  • A man in a blue shirt looks into the camera for a headshot photograph.
    Image attribution tooltip
    Permission granted by Lindus Health
    Image attribution tooltip

    Can a top scientist and Moderna co-founder change the CRO game?

    From his advisory board role at Lindus Health, Robert Langer is aiming to overcome challenges in the CRO market.

    By Feb. 28, 2024
  • digital pill Explore the Trendline
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Artificial intelligence & machine learning

    After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

    By PharmaVoice staff
  • Gianluca Pirozzi header
    Image attribution tooltip
    Permission granted by Gianluca Pirozzi
    Image attribution tooltip
    Profile

    Behind a big-name rare disease biotech, an exec draws from personal experience

    The personal impact of rare disease has shaped Gianluca Pirozzi, a senior vice president at AstraZeneca’s Alexion, as a parent and drug developer.

    By Alexandra Pecci • Feb. 27, 2024
  • An illustration of red blood cells
    Image attribution tooltip
    ismagilov via Getty Images
    Image attribution tooltip

    BioMarin preaches patience amid slow sales for hemophilia gene therapy

    The company earned only $3.5 million last year from its Roctavian treatment, far below the $50 million to $150 million range it had forecast eight months ago.

    By Ben Fidler • Feb. 23, 2024
  • Brent Ragans, U.S. president, Ferring Pharmaceuticals
    Image attribution tooltip
    Permission granted by Ferring Pharmaceuticals
    Image attribution tooltip

    Ferring’s microbiome and gene therapy firsts take the company beyond reproductive health

    Ferring’s U.S. president Brent Ragans discusses the company’s strategy as it expands into new therapeutic areas and further develops its reproductive pipeline.

    By Alexandra Pecci • Feb. 22, 2024
  • chemist in lab with dropper
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    4 biotechs to watch in 2024

    A splashy IPO, first-in-class treatments and upcoming approval dates are a few reasons we’ve got our eyes on these biotechs this year.

    By Alexandra Pecci • Feb. 21, 2024
  • Iovance hallway
    Image attribution tooltip
    Permission granted by Iovance Biotherapeutics
    Image attribution tooltip

    Behind the breakthrough cancer therapy that just won a historic FDA nod

    The first-of-its-kind TIL therapy for solid tumors developed by Iovance Biotherapeutics won FDA approval last week.

    By Kelly Bilodeau • Feb. 21, 2024
  • A man in a suit looking at the camera
    Image attribution tooltip
    Courtesy of Biogen
    Image attribution tooltip

    The roadblocks faced by Biogen are many, but execs point to an R&D-focused turnaround

    A disappointing few years for Biogen have led leadership to use new drug launches as fuel for an about-face.

    By Feb. 15, 2024
  • Drug pill question
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    These 4 drugs had tons of promise — and they flopped. What happened?

    No amount of excitement can prevent failures stemming from safety, efficacy, cost and other speed bumps along the way.

    By Alexandra Pecci • Feb. 13, 2024
  • Brain MRI
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    A new (old) mind-opening tool in the fight against Alzheimer’s disease

    A new use for an existing ultrasound technology is seeing early success in getting medications past the blood-brain barrier.

    By Kelly Bilodeau • Feb. 12, 2024
  • Weight loss drug obesity Ozempic
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Big Pharma players Amgen, Roche and Pfizer seek to follow in Novo and Lilly’s weight loss footsteps

    While Novo Nordisk and Eli Lilly have a sizable lead in the quickly expanding GLP-1 market, Big Pharma peers are looking for a way in.

    By Feb. 8, 2024
  • Pill drug money balance
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    ‘Beginning of the end’ for small molecules? VCs brace for Medicare investment gap

    The "small molecule penalty" becomes even riskier for investors as the IRA negotiates prices, and VCs and lawmakers are looking to get a jump on those headwinds.

    By Feb. 6, 2024
  • rocket ship blasting into space with stars and clouds
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Vaxxinity is brewing up meds for a spacefaring future

    The biotech’s bone- and muscle-building treatments could someday help humans reach other planets. 

    By Kelly Bilodeau • Feb. 5, 2024
  • AZ vaccine
    Image attribution tooltip
    Ricardo Ceppi via Getty Images
    Image attribution tooltip

    Co-inventor of AZ COVID-19 shot pivots from vaccine-linked name

    Barinthus Biotherapeutics wants to be known for more than its pandemic ties, CEO Bill Enright said.

    By Alexandra Pecci • Jan. 30, 2024
  • Exterior sign of Bristol-Myers Squibb
    Image attribution tooltip
    Permission granted by Bristol-Myers Squibb
    Image attribution tooltip

    CAR-T developers respond to FDA black box warning

    Despite a recent safety warning from the FDA, companies such as BMS and J&J stress that the benefits of their cancer therapies still outweigh the risks.

    By Kelly Bilodeau • Jan. 30, 2024
  • neck pain stock
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Tonix closes in on the first new fibromyalgia drug in more than a decade

    In addition to the chronic disease, the non-opioid drug may have applications in other painful conditions.

    By Kelly Bilodeau • Jan. 29, 2024
  • Amylyx CEOs
    Image attribution tooltip
    Permission granted by Amylyx
    Image attribution tooltip
    Q&A

    ‘1 plus 1 equals 3’ — the co-CEO model in pharma

    Amylyx Pharmaceuticals’ co-founders and co-CEOs Josh Cohen and Justin Klee explain their approach to dual leadership and why it can be a good fit in life sciences.

    By Jan. 26, 2024
  • 2024 outlook
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    The biggest questions hanging over pharma in 2024

    Key trends on the horizon in the life sciences this year.

    By Jan. 25, 2024
  • King Charles III
    Image attribution tooltip
    Dan Kitwood/Getty Images via Getty Images
    Image attribution tooltip

    King’s prostate surgery puts spotlight on men’s health — and new cancer treatments on the way

    The publicly announced procedure has highlighted one of the most prevalent and deadly cancers among men, and the treatments being developed to combat it.

    By Jan. 25, 2024
  • Coronavirus
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    The hunt for an elusive universal coronavirus vaccine

    A new study shows that a universal vaccine would lead to huge financial and mortality wins during a pandemic, but development has been slow going.

    By Alexandra Pecci • Jan. 22, 2024
  • hand syringe
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Controversial challenge trials offer unparalleled innovation — with ethical bumps

    Demand for infectious disease treatments is projected to grow and challenge trials, when done right, could speed drug development.

    By Kelly Bilodeau • Jan. 22, 2024
  • Chris Arendt
    Image attribution tooltip
    Permission granted by Takeda Pharmaceuticals
    Image attribution tooltip

    Five years after closing the Shire deal, Takeda is ready to harvest from its latest reinvention

    Amid criticisms of Takeda’s megamerger, the company’s CSO said it has built a pipeline that will deliver.

    By Jan. 19, 2024
  • Pharma progress
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    How to make 2024 a banner year for biopharma, despite the headwinds

    Creative thinking is the name of the game as biopharmas seek to overcome a host of challenges — and investing with purpose, building trust and embracing tech could get them there.

    By Jan. 18, 2024
  • Covid doctor
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    An enduring COVID mystery: Why some do fine and others die

    The infectious disease market could be shifting toward a future not only focused on the microbe, but on the unique genetic attributes of the host.

    By Alexandra Pecci • Jan. 17, 2024
  • gut microbiome
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Pharma takes a gut check of microbiome drugs

    On the heels of two FDA approvals for microbiome-based therapies, interest in the space is gaining steam.

    By Kelly Bilodeau • Jan. 16, 2024